Assembly Biosciences Stock Forecast, Price & News

+0.04 (+1.23 %)
(As of 09/23/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume27,472 shs
Average Volume1.13 million shs
Market Capitalization$148.41 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Assembly Biosciences logo

About Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.09 out of 5 stars

Medical Sector

465th out of 1,351 stocks

Pharmaceutical Preparations Industry

227th out of 664 stocks

Analyst Opinion: 3.2Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

Is Assembly Biosciences a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Assembly Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares.
View analyst ratings for Assembly Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Assembly Biosciences?

Wall Street analysts have given Assembly Biosciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Assembly Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a drop in short interest in August. As of August 31st, there was short interest totaling 1,610,000 shares, a drop of 42.1% from the August 15th total of 2,780,000 shares. Based on an average daily volume of 1,270,000 shares, the short-interest ratio is currently 1.3 days.
View Assembly Biosciences' Short Interest

When is Assembly Biosciences' next earnings date?

Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Assembly Biosciences

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.11. Assembly Biosciences had a negative net margin of 78.57% and a negative trailing twelve-month return on equity of 37.80%.
View Assembly Biosciences' earnings history

How has Assembly Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Assembly Biosciences' stock was trading at $15.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ASMB stock has decreased by 79.0% and is now trading at $3.28.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ASMB?

7 brokers have issued 12 month price objectives for Assembly Biosciences' shares. Their forecasts range from $3.10 to $15.00. On average, they anticipate Assembly Biosciences' share price to reach $8.60 in the next twelve months. This suggests a possible upside of 162.2% from the stock's current price.
View analysts' price targets for Assembly Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the following people:
  • John G. McHutchison, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Jason A. Okazaki, Chief Operating Officer
  • Michael P. Samar, Chief Financial & Accounting Officer
  • Steven J. Knox, Senior Vice President-Clinical Development
  • Luisa M. Stamm, Chief Medical Officer

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

5 employees have rated Assembly Biosciences CEO John McHutchison on John McHutchison has an approval rating of 80% among Assembly Biosciences' employees.

What other stocks do shareholders of Assembly Biosciences own?

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (4.95%), BlackRock Inc. (4.25%), Vanguard Group Inc. (4.19%), Millennium Management LLC (1.18%), Franklin Resources Inc. (1.18%) and Federated Hermes Inc. (1.16%). Company insiders that own Assembly Biosciences stock include Jacqueline Sybil Papkoff, John G Mchutchison, Luisa M Stamm, Richard James Colonno, Timothy A Springer and William E Iv Delaney.
View institutional ownership trends for Assembly Biosciences

Which major investors are selling Assembly Biosciences stock?

ASMB stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Franklin Resources Inc., Northern Trust Corp, JPMorgan Chase & Co., Renaissance Technologies LLC, Geode Capital Management LLC, and Vanguard Group Inc.. Company insiders that have sold Assembly Biosciences company stock in the last year include Jacqueline Sybil Papkoff, John G Mchutchison, Luisa M Stamm, and William E Iv Delaney.
View insider buying and selling activity for Assembly Biosciences
or view top insider-selling stocks.

Which major investors are buying Assembly Biosciences stock?

ASMB stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Millennium Management LLC, Wells Fargo & Company MN, Ergoteles LLC, Morgan Stanley, Morgan Stanley, Tibra Equities Europe Ltd, and Virtu Financial LLC.
View insider buying and selling activity for Assembly Biosciences
or or view top insider-buying stocks.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $3.28.

How much money does Assembly Biosciences make?

Assembly Biosciences has a market capitalization of $147.51 million and generates $79.11 million in revenue each year. The biopharmaceutical company earns $-62,150,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis.

How many employees does Assembly Biosciences have?

Assembly Biosciences employs 139 workers across the globe.

When was Assembly Biosciences founded?

Assembly Biosciences was founded in 2005.

What is Assembly Biosciences' official website?

The official website for Assembly Biosciences is

Where are Assembly Biosciences' headquarters?

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (833) 509-4583 or via email at [email protected].

This page was last updated on 9/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.